Skip to main content
Premium Trial:

Request an Annual Quote

Blueprint Genetics, Archimedlife to Launch Biochemical Rare Disease Testing in North America

NEW YORK – Clinical genetics firm Blueprint Genetics and rare disease diagnostics company Archimedlife Medical Laboratory said today that they have partnered to offer biochemical testing for rare diseases in North America.

Under the agreement, Blueprint Genetics is licensing Archimedlife's technology and tests to offer biochemical testing at its Seattle laboratory, which also provides next-gen sequencing-based genetic testing. The combined testing services will be available in early 2020.

Financial terms and other details of the partnership were not disclosed.

Archimedlife, based in Vienna, provides biochemical and genetic testing for rare diseases, while Blueprint, headquartered in Helsinki, offers clinical genetic testing. Through their collaboration, the companies plan to make a wide variety of genetic disease testing services available in North America, including clinical mass spectrometry and next-generation sequencing.

"The combined global presence and experience in the field allows us to pursue very interesting opportunities together in the North American rare disease space," said Blueprint Genetics CEO Tommi Lehtonen in a statement.

"Now we have the opportunity, together with a powerful and growing genetic testing company, to serve North American customers," said Archimedlife CEO and Founder David Kasper.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.